Improving molecular diagnosis of fabry disease: functional validation of novel splicing variants in GLA
4 affiliations
- 1National Clinical Research Center for Women’s Health and Obstetric & Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- 2Department of Research and Development, Berry Genomics Corporation, Beijing, China
- 3The Laboratory of Clinical Genetics, Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- 4Department of Pediatrics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Abstract
Background: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene. Although genetic testing is the gold standard for FD diagnosis, the identification of numerous splicing variants of unknown pathogenicity poses a significant diagnostic challenge. This uncertainty limits the clinical utility of sequencing in guiding patient management and therapeutic intervention.
Methods: A combination of in silico prediction tools and in vitro minigene splicing assays was utilized to explore the pathogenicity and underlying molecular mechanism of novel deep non-coding variants identified via long-read sequencing in clinically suspected but genetically unsolved patients.
Results: Functional assays revealed that the large deep-intronic insertion c.640-613ins1715 fundamentally disrupts local splicing pattern and introduces new non-canonical splicing sites. It induces a complex array of aberrant events, including partial exon skipping, intron retention, and pseudoexon inclusion, generating five distinct abnormal transcripts alongside residual normal transcript. These aberrant transcripts introduce frameshifts predicted to yield truncated, non-functional proteins. Consequently, this variant was definitively classified as Pathogenic. Conversely, neither the two deep-intronic single nucleotide variants (c.640-363C > T and c.639+761 G > A) nor their cis configuration exhibited aberrant splicing in our minigene system. However, due to the proband’s later-onset FD phenotype, ambiguous population frequencies (gnomAD), and the potential for tissue-specific splicing missed by in vitro models, both variants remain classified as VUS.
Conclusions: This study expands the mutational spectrum of the GLA gene and underscores the complexity of deep-intronic variants. Our findings highlight the critical role of robust functional splicing assays in interpreting variant pathogenicity, establishing accurate genotype-phenotype correlations, and ultimately facilitating precision medicine for FD.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13023-026-04512-1.
Related
- Case Report: A novel intronic FRMD7 variant associated with X-linked infantile nystagmus: functional validation by a minigene splicing assay
- Kinase-based molecular subtyping and a prognostic risk model in colorectal cancer with functional validation of PLK4
- Prenatal diagnosis of CHARGE syndrome in a fetus with a novel CHD7 splicing mutation: A case report.
- From Splicing to Survival: Understanding the Molecular Basis of Prognostic Differences in advanced Small Intestine Neuroendocrine Tumors
- Potential biomarker candidates for improving diagnosis and disease treatment in adenomyosis
BibTeX
@article{zhou2026improving,
title = {{Improving molecular diagnosis of fabry disease: functional validation of novel splicing variants in GLA}},
author = {Jingwen Zhou and Aiping Mao and Jie Feng and Na Hao and Fengxia Yao and Zhengqing Qiu and Danhua Li and Juntao Liu},
journal = {Orphanet Journal of Rare Diseases},
year = {2026},
month = aug,
doi = {10.1186/s13023-026-04512-1},
url = {https://doi.org/10.1186/s13023-026-04512-1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Improving molecular diagnosis of fabry disease: functional validation of novel splicing variants in GLA
AU - Jingwen Zhou
AU - Aiping Mao
AU - Jie Feng
AU - Na Hao
AU - Fengxia Yao
AU - Zhengqing Qiu
AU - Danhua Li
AU - Juntao Liu
PY - 2026
DA - 2026/08/13
JO - Orphanet Journal of Rare Diseases
DO - 10.1186/s13023-026-04512-1
UR - https://doi.org/10.1186/s13023-026-04512-1
AB - Background: Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene. Although genetic testing is the gold standard for FD diagnosis, the identification of numerous splicing variants of unknown pathogenicity poses a significant diagnostic challenge. This uncertainty limits the clinical utility of sequencing in guiding patient management and therapeutic intervention. Methods: A combination of in silico prediction tools and in vitro minigene splicing assays was utilized to explore the pathogenicity and underlying molecular mechanism of novel deep non-coding variants identified via long-read sequencing in clinically suspected but genetically unsolved patients. Results: Functional assays revealed that the large deep-intronic insertion c.640-613ins1715 fundamentally disrupts local splicing pattern and introduces new non-canonical splicing sites. It induces a complex array of aberrant events, including partial exon skipping, intron retention, and pseudoexon inclusion, generating five distinct abnormal transcripts alongside residual normal transcript. These aberrant transcripts introduce frameshifts predicted to yield truncated, non-functional proteins. Consequently, this variant was definitively classified as Pathogenic. Conversely, neither the two deep-intronic single nucleotide variants (c.640-363C > T and c.639+761 G > A) nor their cis configuration exhibited aberrant splicing in our minigene system. However, due to the proband’s later-onset FD phenotype, ambiguous population frequencies (gnomAD), and the potential for tissue-specific splicing missed by in vitro models, both variants remain classified as VUS. Conclusions: This study expands the mutational spectrum of the GLA gene and underscores the complexity of deep-intronic variants. Our findings highlight the critical role of robust functional splicing assays in interpreting variant pathogenicity, establishing accurate genotype-phenotype correlations, and ultimately facilitating precision medicine for FD. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s13023-026-04512-1.
SN - 1750-1172
ER -